Surgery Partners, Inc.
23.225USD
+7.4750 (+47.46%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SGRY.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.12▼ | $0.13 | 2 | 2 |
| Next quarter | $0.15▼ | $0.3 | 0 | 4 |
| Current year | $0.35▼ | $0.46 | 0 | 4 |
| Next year | $0.17▼ | $0.67 | 0 | 2 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.06 | $0.1 | +0.04 (+59.6%) |
| 2026-03-31 | -$0.14 | -$0.03 | +0.11 (+77.8%) |
| 2025-12-31 | $0.3 | $0.12 | -0.18 (-59.7%) |
| 2025-09-30 | $0.16 | $0.13 | -0.03 (-19.0%) |
120 ratings from 19 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| RBC Capital | Reiterated | Outperform | $19 | Sep 30, 2026 |
| TD Cowen | Reiterated | Buy | $19 | Sep 18, 2026 |
| JP Morgan | Maintained | Neutral | $14 $15 | Sep 14, 2026 |
| TD Cowen | Maintained | Buy | $17 $19 | Aug 11, 2026 |
| RBC Capital | Maintained | Outperform | $20 $19 | Aug 11, 2026 |
| Cantor Fitzgerald | Reiterated | Overweight | $18 | Aug 11, 2026 |
| TD Cowen | Maintained | Buy | $28 $20 | Mar 5, 2026 |
| UBS | Maintained | Buy | $29 $21 | Mar 5, 2026 |
| Mizuho | Maintained | Outperform | $19 $17 | Mar 5, 2026 |
| RBC Capital | Maintained | Outperform | $31 $20 | Mar 4, 2026 |
| Barclays | Maintained | Equal-Weight | $18 $14 | Mar 3, 2026 |
| Mizuho | Maintained | Outperform | $22 $19 | Dec 18, 2025 |
| JP Morgan | Maintained | Neutral | $27 $20 | Nov 24, 2025 |
| Barclays | Maintained | Equal-Weight | $24 $18 | Nov 21, 2025 |
| Mizuho | Maintained | Outperform | $28 $22 | Nov 17, 2025 |
| UBS | Maintained | Buy | $34 $29 | Nov 13, 2025 |
| RBC Capital | Maintained | Outperform | $35 $31 | Nov 11, 2025 |
| Benchmark | Maintained | Buy | $35 $30 | Nov 11, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | $36 | Oct 7, 2025 |
| Barclays | Maintained | Equal-Weight | $25 $24 | May 27, 2025 |
| Benchmark | Reiterated | Buy | $35 | Apr 21, 2025 |
| RBC Capital | Reiterated | Outperform | $35 | Mar 25, 2025 |
| Macquarie | Maintained | Outperform | $34 $33 | Mar 11, 2025 |
| JP Morgan | Maintained | Neutral | $38 $28 | Dec 3, 2024 |
| RBC Capital | Maintained | Outperform | $49 $35 | Nov 20, 2024 |
71 filings from 17 insiders · 0 buy / 0 sell over 6m
Officers and directors of SGRY, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DELUCA TERESADirector | Buy | 10.0k | $14.35 | $144k | Aug 18, 2026 |
| DELUCA TERESADirector | Buy | 11.3k | $14.33 | $161k | Aug 18, 2026 |
| HENDRIX BLAIR EDirector | Grant | 34.4k | $14.55 | $500k | Jun 18, 2026 |
| ADLERZ CLIFFORD GDirector | Grant | 11.7k | $13.71 | $160k | Jun 5, 2026 |
| HENDRIX BLAIR EDirector and Beneficial Owner of more than 10% of a Class of Security | Grant | 11.7k | $13.71 | $160k | Jun 5, 2026 |
| TURNER BRENTDirector | Grant | 11.7k | $13.71 | $160k | Jun 5, 2026 |
| DEAN LLOYD HDirector | Grant | 11.7k | $13.71 | $160k | Jun 5, 2026 |
| FORESE LAURA LDirector | Grant | 11.7k | $13.71 | $160k | Jun 5, 2026 |
| DELUCA TERESADirector | Grant | 11.7k | $13.71 | $160k | Jun 5, 2026 |
| DEANE JOHN ADirector | Grant | 11.7k | $13.71 | $160k | Jun 5, 2026 |
| DOHERTY DAVID T.Chief Financial Officer | Sell | 8.9k | $12.50 | $111k | Mar 16, 2026 |
| EVANS JASON ERICChief Executive Officer | Sell | 20.4k | $12.47 | $254k | Mar 16, 2026 |
| BRITTENHAM MARISSAOfficer | Sell | 3.7k | $12.54 | $46k | Mar 13, 2026 |
| BURKHALTER DANIELLEOfficer | Sell | 3.5k | $12.83 | $45k | Mar 13, 2026 |
| BALDOCK JENNIFER BOYDOfficer | Sell | 5.8k | $13.17 | $76k | Mar 12, 2026 |
| DOHERTY DAVID T.Chief Financial Officer | Sell | 14.6k | $13.84 | $202k | Mar 6, 2026 |
| BRITTENHAM MARISSAOfficer | Sell | 8.8k | $13.70 | $120k | Mar 6, 2026 |
| BURKHALTER DANIELLEOfficer | Sell | 7.7k | $13.60 | $105k | Mar 6, 2026 |
| WEBB WILLIAM TRENTONOfficer | Sell | 2.1k | $13.86 | $29k | Mar 6, 2026 |
| BALDOCK JENNIFER BOYDOfficer | Sell | 10.1k | $13.70 | $138k | Mar 6, 2026 |
No analyst notes on SGRY yet.
Analyst Ratings
6 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 4 | 3 | 0 | 0 | Buy2.43 |
| 1 mo ago | 1 | 8 | 3 | 0 | 0 | Buy2.17 |
| 2 mo ago | 1 | 8 | 3 | 0 | 0 | Buy2.17 |
| 3 mo ago | 1 | 8 | 3 | 0 | 0 | Buy2.17 |
Members whose judged calls on SGRY have played out most reliably.
No settled calls on SGRY yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice